Pladienolide Derivatives, Cancer Treatment, Apr 15
Summary
The European Patent Office published patent application EP3774760A1 on April 15, 2026, covering pladienolide derivatives as spliceosome targeting agents for treating cancer. The application was filed by Eisai R&D Management Co., Ltd. and names 11 inventors including Andrew Cook, Jason T. Lowe, and Sudeep Prajapati. The patent designates multiple European states including AT, BE, DE, FR, GB, IT, NL, and SE, among others.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.
What changed
The European Patent Office published patent application EP3774760A1 for pladienolide derivatives as spliceosome targeting agents for treating cancer, filed by Eisai R&D Management Co., Ltd. The application covers pharmaceutical compositions containing these compounds and methods of treating cancer using them.
For pharmaceutical companies developing spliceosome-targeting oncology therapeutics, this patent publication establishes priority dates and published claims that may affect freedom-to-operate assessments. Companies in this therapeutic space should review the published claims to evaluate potential overlap with their own R&D programs.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PLADIENOLIDE DERIVATIVES AS SPLICEOSOME TARGETING AGENTS FOR TREATING CANCER
Publication EP3774760A1 Kind: A1 Apr 15, 2026
Applicants
Eisai R&D Management Co., Ltd.
Inventors
COOK, Andrew, LOWE, Jason T., PRAJAPATI, Sudeep, SAMARAKOON, Thiwanka, BRAWN, Ryan, REYNOLDS, Dominic, ZHONG, Cheng, ELLERY, Shelby, LIU, Xiang, SHEEHAN, Megan, PALACINO, James
IPC Classifications
C07D 313/00 20060101AFI20260311BHEP C07D 405/06 20060101ALI20260311BHEP C07D 405/10 20060101ALI20260311BHEP C07D 405/14 20060101ALI20260311BHEP C07D 498/08 20060101ALI20260311BHEP C07D 491/10 20060101ALI20260311BHEP A61K 31/365 20060101ALI20260311BHEP A61K 31/496 20060101ALI20260311BHEP A61K 31/5377 20060101ALI20260311BHEP A61K 31/416 20060101ALI20260311BHEP A61K 31/4025 20060101ALI20260311BHEP A61K 31/4545 20060101ALI20260311BHEP A61P 35/00 20060101ALI20260311BHEP A61P 35/02 20060101ALI20260311BHEP A61P 35/04 20060101ALI20260311BHEP A61K 39/00 20060101ALN20260311BHEP A61K 31/497 20060101ALN20260311BHEP A61K 31/513 20060101ALN20260311BHEP A61K 31/54 20060101ALN20260311BHEP A61K 31/55 20060101ALN20260311BHEP A61K 39/39 20060101ALN20260311BHEP A61K 45/06 20060101ALN20260311BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.